September 15, 2021 5:09pm

The Biostage (BSTG) Chronicles: Same and usual “tricks” as the customary “pump/promote” continued, Wednesday opened down -$0.04 (404 shares traded) and then promptly jumped +$0.52 with 17,107 shares traded as the session closed. The SEC should question who or which entity is buying these shares – there is a pattern?

Pre-open indications: 4 HITs and 2 MISS

My comments try to distinguish the temporary from real pricing digression or progress with a 360-degree view.

I used to think negativity was a state of mind. Now, having watched for long enough, I come to realize negativity can be a character trait


The Dow closed UP +236.82 points (+0.68%); the S&P closed UP +37.65 points (+0.85%) while the Nasdaq closed UP +123.77 points (+0.82%)

 

Henry’omics:

Indexes and the stem, cell and gene therapy sector rebounded Wednesday after a string of negative trading sessions.

Markets have been in a funk so far this month amid rising investor worries about the delta variant derailing the economic recovery, along with hand-wringing over the next action by the Federal Reserve. <CNBC>

Noted Update: Moderna (MRNA) released more data on so-called breakthrough cases it says supports the push for the wide use of Covid-19 vaccine booster shots. MRNA shared a new analysis from its phase three study that showed the incidence of breakthrough Covid cases, which occur in fully vaccinated people, was less frequent in a group of trial participants who were more recently inoculated, suggesting immunity for earlier groups had started to wane.

  • FDA scientists declined to take a stance on whether to back booster shots of Pfizer’s Covid vaccine, saying U.S. regulators haven’t verified all the available evidence.

The FDA appears to be skeptical about some of the data provided, including efficacy numbers out of Israel, where researchers there have released observational studies showing the effectiveness of the Pfizer vaccine against infection waned over time. <CNBC>

 

Data Docket: The New York Fed’s Empire Index, a measure of manufacturing in the region, came in at 34.3 for September, way ahead of the 18 consensus estimate from FactSet and an acceleration from August.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Wednesday opened positive at 19/13, 2 flats and 1 acquired, stayed positive at the mid-day at 21/12, 1 flat and 1 acquired, closing positive at 18/15, 2 flats and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: after six (6) negative of the last ten (10) sessions – a few buy maybes but, be cautionary and selective in moves” …  https://www.regmedinvestors.com/articles/12095

 

Pre-open results: 4 Hits - <BUY: Cellectis SA (CLLS +$0.14), CRISPR Therapeutics (CRSP +$0.96), Sage Therapeutics (SAGE +$1.38), BioLife Solutions (BLFS -$3.00) > 2 Miss <Applied Genetic Technologies (AGTC -$0.04), Biostage (BSTG +$0.52 – “pumped”)>

 

The Biostage (BSTG) Chronicles: “The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?”https://www.regmedinvestors.com/articles/12087

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23

 

Key Metric - volume:

  • Sector volume was LOW with 6 of the 18-upside having higher than the 3-month average volume with very LOW volume of 4 of 14-downside having higher than the 3-month average volume;

 

The Biostage (BSTG) Chronicles: The usual “pump/promote”, Wednesday opened down -$0.04 (404 shares traded) and then promptly jumped +$0.52 with 17,107 shares traded after Tuesday closed down -$0.27 to $3.56 with 6,551 shares traded following Monday’s +$0.04 to $3.83 with 26,150 shares traded, Fridays closed down -$0.19 to $3.79 with 22,124 shares traded after Thursday traded up +$0.66 to $3.98 with 6,0622 shares traded, Wednesday traded +$0.57 with 7,833 shares traded after last Tuesday closing down -$0.75 to $2.75 with 6,705 shares traded.

  • Today is just another fact, how the share trades with the “push/promote” - another typical example,
  • WHAT is BSTG’s value proposition, after all the share price “pumping”?
  • Is management responding to U.S./non-U.S./ Chinese investors complaints after the last (listed pricing) private placement of $4.71?
  • Where are these buying monies coming from?

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Ultragenyx (RARE), Fate Therapeutics (FATE), Sage Therapeutics (SAGE), CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS) to name 5 of the 18 inclining of the 35 covered

Hammered in today’s market:

  • Intellia therapeutics (NTLA), BioLife Solutions (BLFS), ReNeuron (RENE.L), Regenxbio (RGNX), Alnylam Pharmaceuticals (ALNY) to name 5 of the 14 declining of the 35 covered

Closing flat:

  • 2 – Caladrius Biosciences (CLBS), Adverum Biotechnologies (ADVM) and 1- Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed up +1.10% and XBI closed up +1.12%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -1.28 points or -6.58% at 18.18

 

September, the third month of Q3/21:

Wednesday closed positive with 18 advancers, 14 decliners, 2 flat and 1 acquired

Tuesday closed negative with 5 advancers, 29 decliners and 1 acquired

Monday (9/13) closed negative with 15 advancers, 19 decliners and 1 acquired

 

The BOTTOM LINE: What did I say this morning, “I keep reinforcing the theme that increased stock market volatility … had suppressed the stem, cell and gene therapy sector (SC&GT); yet the more oversold – the greater the capacity to selectively … rebound as an avenue to profiting.

SC&GT stocks were “performing”, bouncing back after the previous three (3) session’s downslide; even as the Russell 2000 finished with a gain of 1%.

The Nasdaq advanced 0.8% at 15,161, marking its best day since Aug. 30; helping the SC&GT sector

Issue, the risk-on sentiment gained momentum through the session.

Or it could say buying opportunities are here today and maybe tomorrow but G O N E soon!

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.